Comparison of Safety of Subcutaneous Enoxaparin as Outpatient Anticoagulation Bridging Therapy in Patients With a Mechanical Heart Valve Versus Patients With Nonvalvular Atrial Fibrillation

American Journal of Cardiology

Volumn 104, Issue 10, 2009, Pages 1429-1433

  Bui, Hien Thuy ^a,b   Krisnaswami, Ashok ^a   Le, Chieu Uyen ^a   Chan, James ^c   Shenoy, Bach Nga ^a  

^a San Jose Medical Center   (United States)

^b KAISER PERMANENTE   (United States)

^c Pharmacy Outcomes Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; WARFARIN;

ADULT; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COHORT ANALYSIS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT PLANNING;

AGED; AMBULATORY CARE; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; ENOXAPARIN; FEMALE; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PREMEDICATION; RETROSPECTIVE STUDIES; SURGICAL PROCEDURES, OPERATIVE; THROMBOEMBOLISM;

EID: 72049125866     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.065     Document Type: Article

References (16)

1. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl (2004) 204S-233S
2. Fuster V. ACC/AHA/ESC 2006 guidelines for the management of atrial fibrillation. J Am Coll Cardiol 48 (2006) e149-e246
3. Singer D.E., Albers G.W., Dalen J.E., Fang M.C., Go A.S., Halperin J.L., Lip G.Y.H., and Manning W.J. Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 suppl (2008) 546S-592S
4. Singer D.E., Albers G.W., Dalen J.E., Go A.S., Halperin J.L., and Manning W.J. Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 suppl (2004) 429S-456S
5. Schulman S., and Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005) 692-694
6. Ferreira I., Dos L., Tornos P., Nicolau I., Permanyer-Miralda G., and Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocoumarol. Heart 89 (2003) 527-530
7. Kovacs M.J., Kearon C., Rodger M., Anderson D.R., Turpie A.G.G., Bates S.M., Desjardins L., Douketis J., Kahn S.R., Solymoss S., and Wells P.S. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 110 (2004) 1658-1663
8. Douketis J.D., Johnson J., and Turpie A.B. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin. Arch Intern Med 164 (2004) 1319-1326
9. Jaffer A.K., Ahmed M., Brotman D.J., Bragg L., Seshadri N., Qadeer M.A., and Klein A. Low-molecular-weight-heparin as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 20 (2005) 11-16
10. Halbritter K.M., Wawer H.A., Beyer J., Oettler W., and Schellong M. Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost 3 (2005) 2823-2825
11. Spyropoulos A.C., Turpie A.G.G., Dunn A.S., Spandorfer J., Douketis J., Jacobson A., and Frost F.J. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 4 (2006) 1246-1252
12. Spyropoulos A.C., Frost F.J., Hurley J.S., and Robert M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 125 (2004) 1642-1650
13. Salem D.N., Stein P.D., Al-Ahmad A., Bussey H.I., Horstkotte D., Miller N., and Pauker S.G. Antithrombotic therapy in valvular heart disease-native and prosthetic: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 suppl (2004) 457S-482S
14. Douketis J.D., Berger P.B., Dunn A.S., Jaffer A.K., Spyropoulos A.C., Becker R.C., and Ansell J. The perioperative management of antithrombotic therapy. Antithrombotic and thrombolytic Therapy, 8th ED: ACCP guidelines. Chest 133 suppl (2008) 299S-339S
15. Carrel T.P., Klingenmann W., Mohacsi P.J., Berdat P., and Althaus U. Perioperative bleeding and thromboembolic risk during non-cardiac surgery in patients with mechanical prosthetic heart valves: an institutional review. J Heart Valve Dis 8 (1999) 392-398
16. In: Butchart E.G., and Bodnar E. (Eds). Thrombosis, Embolism and Bleeding (1992), ICR Publishers, London 293-331